Dacomitinib (Vizimpro): Irreversible EGFR Inhibitor for Lung Cancer
Dacomitinib represents a significant upgrade in lung cancer therapy. Unlike first-generation drugs that act like "Velcro" (binding temporarily), Dacomitinib acts like "Superglue." It is an irreversible EGFR inhibitor.
This means it binds permanently to the cancer cell's receptors, completely shutting down the growth signals. Because of this irreversible grip, Dacomitinib (Vizimpro) provides a more sustained blockade against tumor growth compared to older reversible inhibitors.
It is an oral daily medication designed for patients with specific genetic mutations, offering a powerful first-line treatment option.
Indications
- Non-Small Cell Lung Cancer (NSCLC): First-line treatment for adults with metastatic NSCLC.
- Crucial Requirement: Effective only in patients with confirmed EGFR activating mutations (Exon 19 deletion or Exon 21 L858R substitution). A genetic test is mandatory before starting therapy.
Dosage and administration
Consistency is key for this irreversible inhibitor.
- Standard Dose: 45 mg taken orally once daily.
- Instructions: Swallow the tablet whole with water. It can be taken with or without food. Try to take it at the same time every day.
- Missed Dose: Only take the missed dose if your next scheduled dose is more than 12 hours away. Otherwise, skip it.
- Pregnancy: Dacomitinib can cause fetal harm. Effective contraception is strictly required.
- Severe hepatic impairment.
- History of interstitial lung disease (ILD).
Because the drug binds permanently, skin and gut reactions are common and need management.
- Skin (Very Common): Acne-like rash, dry skin, and paronychia (painful infection/inflammation around the fingernails or toenails). Moisturizers are essential.
- Digestive: Diarrhea is the most frequent side effect. Have anti-diarrheal medication ready at home just in case. Stomatitis (mouth sores) may also occur.
- Eyes: Dry eyes or conjunctivitis.
